Check for updates

REVIEW

Non-headache symptoms in migraine patients [version 1; peer review: 2 approved]

Ping-Kun Chen¹⁻³, Shuu-Jiun Wang ⁴⁻⁶

¹School of Medicine, China Medical University, Taichung, Taiwan

²Bo-Zhi Neurology Clinic, Taichung, Taiwan

³Department of Neurology, China Medical University Hospital, Taichung, Taiwan

⁴School of Medicine, National Yang-Ming University, Taipei, Taiwan

⁵Brain Research Center, National Yang-Ming University, Taipei, Taiwan

⁶Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan

V1 First published: 14 Feb 2018, 7(F1000 Faculty Rev):188
<https://doi.org/10.12688/f1000research.12447.1>

Latest published: 14 Feb 2018, 7(F1000 Faculty Rev):188
<https://doi.org/10.12688/f1000research.12447.1>

Abstract

Migraine is one of the most common neurological disorders. In addition to severe headaches, non-headache symptoms associated with migraine attacks as well as co-morbid disorders frequently aggravate the disabling of migraine patients. Some of these symptoms are related to poor outcomes. In this review, we update the advances of studies on certain non-headache symptoms, including visual disturbance, gastrointestinal symptoms, allodynia, vestibular symptoms, and symptoms of co-morbid restless legs syndrome and psychiatric disorders.

Keywords

migraine, visual disturbance, allodynia, restless legs syndrome, depression

Open Peer Review

Approval Status

	1	2
version 1
14 Feb 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Charly Gaul**, Migraine and Headache
Clinic Königstein, Königstein im Taunus,
Germany
2. **Andrew Charles**, University of California, Los
Angeles, Los Angeles, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Shuu-Jiun Wang (sjwang@vghtpe.gov.tw)

Author roles: **Chen PK:** Conceptualization, Formal Analysis, Writing – Original Draft Preparation; **Wang SJ:** Conceptualization, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This study was supported in part by grants from Brain Research Center, National Yang-Ming University and Ministry of Health and Welfare, Taiwan [MOHW 105-TDU-B-211-113-003, MOHW 106-TDU-B-211-113001].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Chen PK and Wang SJ. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chen PK and Wang SJ. **Non-headache symptoms in migraine patients [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):188 <https://doi.org/10.12688/f1000research.12447.1>

First published: 14 Feb 2018, 7(F1000 Faculty Rev):188 <https://doi.org/10.12688/f1000research.12447.1>

Introduction

Migraine is a very common neurological disorder characterized by recurrent episodes of disabling headache. In addition to headaches, there are many different non-headache symptoms during or between migraine attacks. These non-headache symptoms of migraine also impact patients' daily activities as well as their quality of life. In this brief review, we focus on the recent findings of several common non-headache symptoms of migraine, including visual disturbance, gastrointestinal symptoms, allodynia, vestibular symptoms, and symptoms of co-morbid restless legs syndrome (RLS) and psychiatric disorders. Of note, there are a variety of other symptoms, such as phonophobia, neck pain, cognitive dysfunction, and fatigue, which are not discussed in this review.

Visual disturbance

Visual disturbance is common in patients with migraine. It is an important premonitory symptom: 32% of patients experience light sensitivity and 21% have difficulties in focusing vision¹. Photophobia and visual aura are two major types of visual disturbance. Photophobia is more persistent, whereas visual aura is more transient and discrete. In fact, photophobia may begin in the premonitory phase and persist throughout the migraine attack. Up to 80% of migraine patients have experienced photophobia during an attack². In addition, visual aura is the most common aura and usually occurs in isolation, whereas the other forms of aura usually occur with visual symptoms³. Actually, different types of aura, which may reflect the activation of different parts of the brain (for example, visual and sensory aura), could start at the same time or in succession⁴. In a Brazilian study on 122 migraine with aura patients, the most common visual symptoms were blurred vision (54.1%) and small bright dots (47.5%), whereas the frequencies of classic zigzag or jagged lines and the typical "C" crescentic shape were 41.8% and 16.4%, respectively⁵. Hansen *et al.* analyzed more than 1,000 attacks of migraine aura without headache in a single patient for 18 years. The classic aura initially propagated predominantly in the central visual fields and then spread to upper and temporal fields on both sides⁶. They also found that the visual auras disappeared for several minutes before reappearing in a distant location. In this patient, the auras propagating from V1 to V2 regions of the occipital cortex were suspected to correspond to the visual percept from a scintillating wave to a scotoma⁶.

Visual snow is very rare and is described as a persistent disturbance in the entire visual field similar to the noise of an analogue television. It is frequently reported to be persistent at all times when eyes are both open and closed. Patients with visual snow were often diagnosed as having persistent visual aura. However, visual snow is frequently concomitant with migraine but usually not responsive to standard migraine treatment⁷. In addition, patients with visual snow comorbid with migraine frequently have other visual symptoms such as photopsia, nyctopia, and palinopsia^{7,8}. In an [18F]-flurodeoxyglucose PET study, hypermetabolism of the right lingual gyrus and the anterior lobe of the left cerebellum were noted in patients with visual snow but not seen for interictal migraine patients alone⁷.

Schankin *et al.* suggest that visual snow is a unique visual disturbance, distinct from migraine with aura. However, the pathophysiology may be associated with migraine as well⁸.

Gastrointestinal disturbance

Gastrointestinal symptoms are common accompanying symptoms of migraine. Nausea occurs in 70–80%^{9,10} and vomiting in 30% of migraine patients². Anorexia is also common in migraine patients. However, because of the different study methods, the frequency of anorexia is variable from less than 20 to more than 82%^{11–13}. In addition, migraine patients experienced delayed gastric emptying during and outside of a migraine attack^{14,15}. The head-HUNT study in Norway showed that gastrointestinal complaints increased with increasing headache frequency, including migraine¹⁶. In a recent report of the American Migraine Prevalence and Prevention (AMPP) study, persistent frequent headache-related nausea, defined as nausea frequency of more than 50% within 2 years, was common (43.7%) among subjects with episodic migraine. Migraine patients with frequent nausea were twice as likely to progress to chronic migraine (CM) compared to those with no or a low frequency of nausea¹⁷. Autonomic nervous system dysfunction is suspected to be related to migraine patients with gastrointestinal symptoms^{18,19}. In one PET study, activation of the rostral dorsal medulla and periaqueductal gray was noted in patients with nausea as a premonitory symptom²⁰. Anorexia is a major symptom of abdominal migraine, a variant of migraine with recurrent abdominal pain, mainly in children. About 70% of them develop migraine in adults. Abdominal migraine can persist into adulthood in some patients²¹.

Allodynia

Allodynia is a painful sensation caused by innocuous stimuli, such as light touch, brushing hair, wearing glasses, and so on. It was reported in 70% of episodic migraine and in 90% of CM patients^{22,23} and was associated with anxiety, depression, and disability²⁴. The risk factors of allodynia in migraine patients included obesity, high frequency of headache, and female gender²⁵. Allodynia usually develops within a few hours after migraine attack and is associated with inconsistency of response to triptans from one attack to another within patients²⁶. The AMPP study showed that allodynia was associated with a lower efficacy of acute medications^{27,28}. The poor and inconsistent response to triptans and other abortive medications is explained by the fact that allodynia is the clinical manifestation of central sensitization^{29,30}. The activation of second-order neurons in the brainstem, particularly the trigeminal nucleus caudalis, is related to cephalic allodynia. If the allodynia is noted in other sites outside of the head, sensitization of the third-order trigeminal neurons in the posterior thalamic nuclei is suspected^{23,26,31}.

Two blood oxygen level-dependent (BOLD)-fMRI studies demonstrated abnormal activations in migraine patients with allodynia^{32,33}. However, the activation sites were not consistent. In one study, the activation of the dorsal pons and contralateral inferior parietal lobule were lower in migraine patients with allodynia³². In the other study, greater activation at the anterior

cingulate cortex and middle frontal gyrus was observed in migraine patients with allodynia during moderate-noxious trigeminal heat stimulation (51°C) but lower activation in the secondary somatosensory cortices was seen during high-noxious trigeminal heat stimulation (53°C)³³. The authors suspected a dysfunctional analgesic compensatory mechanism and an abnormal internal representation of pain in migraine patients with allodynia^{32,33}. Very recently, a PET study with [¹¹C] raclopride found that there is a transient dopamine reduction in the striatum region during migraine attacks and allodynia. However, a relatively sudden increased dopamine release in the insula was noted during allodynia, the late stage of migraine attack. The authors suspected that the reduction and imbalance of dopamine between striatum region and insula account for the pathogenesis of the allodynia³⁴.

Schwedt *et al.* showed that, in addition to allodynia during migraine attack, low heat pain thresholds between migraine attacks were found in migraine patients and the thresholds were positively correlated with the number of hours until the next migraine attack. The authors suspected that the lowered pain threshold was an early sign of a migraine attack³⁵. Similar findings were also found in a small-sized study: the lower pain thresholds were detected during the pre-attack phase of migraine but not during the interictal period³⁶.

Vestibular symptoms

About 30–50% of migraine patients report vertigo, dizziness, or balance disturbances associated with migraine attack^{37–39}. The frequency of vestibular symptoms is much higher in patients with migraine than in those with other headache types^{40,41}.

Several terms have been used to describe vertigo occurring with migraine. The term “vestibular migraine” was co-defined by the International Headache Society and Barany society. The criteria for vestibular migraine are listed in the Appendix of International Classification of Headache Disorders, third beta edition⁴². Both migraine and vestibular symptoms are very common in the population and therefore co-existence is possible. It is important to note the similarity of migraine with brainstem aura and vestibular migraine. In migraine patients with brainstem aura, vertigo is one of the aura symptoms. Of note, at least two aura symptoms of brainstem origin are necessary to make the diagnosis of migraine with brainstem aura, including dysarthria, vertigo, tinnitus, hypacusis, diplopia, ataxia, and decreased level of consciousness. The auras should be accompanied or followed by the headache within 60 minutes⁴². The diagnosis of vestibular migraine requires the exclusion of other potential causes of the vestibular symptoms. It usually consists of a detailed history of both headache and vestibular components in addition to potential testing, such as imaging and audiometry. The auditory symptoms, such as hearing loss, tinnitus, and aural pressure/fullness, are common but usually mild in vestibular migraine patients^{43,44}.

The vertigo symptoms vary in patients with migraine. They can occur spontaneously without any trigger or may be provoked by positional change⁴⁵. The frequency of spontaneous vertigo seems to be much higher than positional vertigo in patients

with vestibular migraine⁴⁵. In a recent study with a nine-year follow-up, the accompanying vertigo could be persistent during migraine attacks, which caused a severe impact on quality of life. The authors also reported increased interictal ocular motor abnormalities from 16 to 41% at follow-up⁴³.

The pathophysiology of vestibular migraine is still unclear. The activation of vestibular and cranial nociceptive pathways at the same time was suspected to be one possible cause. Recently, several neuroimaging studies support the possibility. One whole-brain BOLD-fMRI study showed abnormal thalamic functional response to vestibular stimulation in patients with vestibular migraine⁴⁶. In a recent MRI study for structural changes, increased gray matter volume of the left thalamus, left temporal lobe, frontal lobe, and occipital lobes as well as decreased gray matter volume of the left cerebellum were found in patients with vestibular migraine compared to migraine patients without vestibular symptoms⁴⁷. During the attacks of vestibular migraine, fludeoxyglucose PET scans demonstrated increased metabolism in the temporo-parieto-insular areas and bilateral thalamic regions. The finding indicates activation of the vestibulo-thalamo-cortical pathway⁴⁸.

There are only a few studies focusing on the treatment of vestibular migraine⁴⁹. Patients are often treated with typical migraine prophylaxis. Zolmitriptan was reported to be better than placebo during acute attack of vestibular migraine⁵⁰. In addition, flunarizine was shown to be an effective preventive agent for vestibular migraine⁵¹.

Actually, vertigo is very common in the general population⁵². The associations between migraine and benign paroxysmal positional vertigo (BPPV) have been reported. One study revealed that migraine was three times more common in patients with BPPV than in the general population⁵³. Another population-based study in Taiwan showed that patients with migraine had a 2.03-fold increased risk of developing BPPV compared with the control group⁵⁴.

Restless legs syndrome

The relationship between migraine and sleep has been known for more than a century⁵⁵. Sleep disturbance is not only a common complaint of migraine patients but also a trigger of migraine attack⁵⁶. There is accumulating evidence to show that RLS, an important cause of sleep disturbance, is one of the comorbidities of migraine^{57–64}. Some similarities are noted between migraine and RLS—e.g. female predominant, episodic attacks, and fluctuations in levels of certain biogenic amines during attacks—and are postulated as crucial factors in the pathophysiology^{65–67}. The frequency of RLS in migraine patients is variable (about fourfold increased odds compared to healthy controls); however, it is lower in Asians but higher in non-Asians. The frequency of RLS in migraine patients did not differ between genders or those with and without aura^{57–64}.

The pathophysiology of the association is still unknown. However, some clinical findings provide clues. A recent study of a temporal relationship between migraine and RLS attacks

showed bidirectional triggering association between migraine and RLS attacks in migraine patients with comorbid RLS⁶⁸. In addition, migraine patients with RLS were more likely to have photophobia, phonophobia, exacerbation due to physical activities, vertigo, dizziness, tinnitus, and neck pain⁵⁷. The results suggest that migraine severity is related to RLS frequency and explain the reason why the propensity of RLS is higher in clinic-based studies as compared to community studies^{57–64}. Valente *et al.* reported a higher familial predisposition to serotonergic drugs in migraine patients with RLS⁶⁹. In a genetic study, Fuh *et al.* demonstrated that *MEIS1* variants, a known gene for RLS alone, are also associated with an increased risk of RLS in migraine patients⁷⁰. All of these reports hint that the balance of dopaminergic and serotonergic systems could be crucial in the association between migraine and RLS.

Psychiatric disorders

Migraine is comorbid with many psychiatric disorders⁷¹. Of them, depression, bipolar disorder, and anxiety disorder are common and cause disability in affected patients⁷².

Depression

Epidemiology studies demonstrate that migraine subjects are at two- to fourfold increased risk of developing lifetime major depression in comparison with subjects without migraine^{73–75}. The association is stronger in migraine with aura than in migraine without aura^{76,77}. In addition, CM patients had a higher risk of depression as compared to patients with episodic migraine^{78,79}.

The pathophysiology of this comorbid association is not known, but genetic factors, serotonergic dysfunction, ovarian hormone influences, and hypothalamic-pituitary adrenal axis dysregulation are suspected to be involved long term⁸⁰. Lirng *et al.* recently measured brain metabolite concentrations, including myo-inositol (mI) and total creatine (tCr), by MR spectroscopy. They demonstrated that migraine patients with major depression had higher mean mI:tCr ratios in the left and right dorsolateral prefrontal cortex compared to migraine patients without major depression⁸¹.

Bipolar disorder

Migraine patients are reported to have a higher risk of comorbid bipolar disorder^{82–84}. Bipolar patients are also reported to have a higher frequency of migraine, particularly among bipolar disorder II subjects⁸⁵. Of note, bipolar disorder relative risk is increased to 3.88 in CM compared to normal controls and 1.81 compared

to episodic migraine⁸⁶. In addition, patients comorbid with migraine and bipolar disorder seem to be more likely to have a rapid cycling illness course^{87,88}.

Anxiety

The prevalence of anxiety is about two to five times higher in patients with migraine than in the general population⁸⁹. Similar to other psychiatric comorbidities, anxiety is much more common in CM patients than in those with episodic migraine⁹⁰. Alessandra *et al.* recruited 1,261 migraine patients in Brazil and classified them into four groups based on migraine frequency. In comparison with controls, the migraine patients had a higher risk of generalized anxiety disorder and the risk increased with headache frequency. Similar comorbid associations were also noted in panic disorder and obsessive-compulsive disorder⁹¹. The risk of panic disorder was also reported to be 3.6 times higher in migraine patients in a meta-analysis from 1990–2012. The presence of panic disorder in migraine patients is associated with more frequent attacks, increased disability, a higher risk for chronification, and medication overuse⁹². In addition, osmophobia in migraine patients is reported to be associated with significant anxiety symptoms⁹³.

Conclusions

Migraine is a disabling neurological disorder, not only because of the headaches. Many non-headache symptoms and comorbidities of migraine have a significant negative impact on patients' quality of life. There are many more studies focusing on this issue. For better quality and strategy of migraine patients' care, more studies need to be conducted to explicitly investigate these problems from a therapeutic point of view, given the clinical implications.

Competing interests

The authors declare that they have no competing interests.

Grant information

This study was supported in part by grants from Brain Research Center, National Yang-Ming University and Ministry of Health and Welfare, Taiwan [MOHW 105-TDU-B-211-113-003, MOHW 106-TDU-B-211-113001].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Laurell K, Artto V, Bendtsen L, *et al.*: **Premonitory symptoms in migraine: A cross-sectional study in 2714 persons.** *Cephalgia*. 2016; **36**(10): 951–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
2. Choi JY, Oh K, Kim BJ, *et al.*: **Usefulness of a photophobia questionnaire in patients with migraine.** *Cephalgia*. 2009; **29**(9): 953–9. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Russell MB, Olesen J: **A nosographic analysis of the migraine aura in a general population.** *Brain*. 1996; **119**(Pt 2): 355–61. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Viana M, Linde M, Sances G, *et al.*: **Migraine aura symptoms: Duration, succession and temporal relationship to headache.** *Cephalgia*. 2016; **36**(5): 413–21. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
5. Queiroz LP, Friedman DI, Rapoport AM, *et al.*: **Characteristics of migraine visual**

- aura in Southern Brazil and Northern USA. *Cephalalgia*. 2011; 31(16): 1652–8. [PubMed Abstract](#) | [Publisher Full Text](#)
6. **F** Hansen JM, Baca SM, Vanvalkenburgh P, *et al.*: Distinctive anatomical and physiological features of migraine aura revealed by 18 years of recording. *Brain*. 2013; 136(Pt 12): 3589–95. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 7. Schankin CJ, Maniyar FH, Sprenger T, *et al.*: The relation between migraine, typical migraine aura and “visual snow”. *Headache*. 2014; 54(6): 957–66. [PubMed Abstract](#) | [Publisher Full Text](#)
 8. Schankin CJ, Maniyar FH, Digre KB, *et al.*: ‘Visual snow’ - a disorder distinct from persistent migraine aura. *Brain*. 2014; 137(Pt 5): 1419–28. [PubMed Abstract](#) | [Publisher Full Text](#)
 9. Kurth T, Holtmann G, Neufang-Hüber J, *et al.*: Prevalence of unexplained upper abdominal symptoms in patients with migraine. *Cephalalgia*. 2006; 26(5): 506–10. [PubMed Abstract](#) | [Publisher Full Text](#)
 10. Lipton RB, Stewart WF, Diamond S, *et al.*: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. *Headache*. 2001; 41(7): 646–57. [PubMed Abstract](#) | [Publisher Full Text](#)
 11. Martins KM, Bordini CA, Bigal ME, *et al.*: Migraine in the elderly: a comparison with migraine in young adults. *Headache*. 2006; 46(2): 312–6. [PubMed Abstract](#) | [Publisher Full Text](#)
 12. Rasmussen BK, Jensen R, Olesen J, *et al.*: A population-based analysis of the diagnostic criteria of the International Headache Society. *Cephalalgia*. 1991; 11(3): 129–34. [PubMed Abstract](#) | [Publisher Full Text](#)
 13. Blau JN: What some patients can eat during migraine attacks: therapeutic and conceptual implications. *Cephalalgia*. 1993; 13(4): 293–5. [PubMed Abstract](#) | [Publisher Full Text](#)
 14. Aurora S, Kori S, Barrodale P, *et al.*: Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. *Headache*. 2007; 47(10): 1443–6. [PubMed Abstract](#) | [Publisher Full Text](#)
 15. Aurora SK, Kori SH, Barrodale P, *et al.*: Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. *Headache*. 2006; 46(1): 57–63. [PubMed Abstract](#) | [Publisher Full Text](#)
 16. Aamodt AH, Stovner LJ, Hagen K, *et al.*: Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study. *Cephalalgia*. 2008; 28(2): 144–51. [PubMed Abstract](#)
 17. **F** Reed ML, Fanning KM, Serrano D, *et al.*: Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results. *Headache*. 2015; 55(1): 76–87. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 18. Peroutka SJ: Re: a sympathetic view of “2003 Wolff Award: possible parasympathetic contributions to peripheral and central sensitization during migraine”. *Headache*. 2004; 44(7): 731–2; author reply 732–3. [PubMed Abstract](#) | [Publisher Full Text](#)
 19. Chelmsky TC, Chelmsky GG: Autonomic abnormalities in cyclic vomiting syndrome. *J Pediatr Gastroenterol Nutr*. 2007; 44(3): 326–30. [PubMed Abstract](#) | [Publisher Full Text](#)
 20. Maniyar FH, Sprenger T, Schankin C, *et al.*: The origin of nausea in migraine-PET study. *J Headache Pain*. 2014; 15: 84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Dignan F, Abu-Arafeh I, Russell G: The prognosis of childhood abdominal migraine. *Arch Dis Child*. 2001; 84(5): 415–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Bigal ME, Ashina S, Burstein R, *et al.*: Prevalence and characteristics of allodynia in headache sufferers: a population study. *Neurology*. 2008; 70(17): 1525–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. **F** Louter MA, Bosker JE, van Oosterhou WP, *et al.*: Cutaneous allodynia as a predictor of migraine chronification. *Brain*. 2013; 136(Pt 11): 3489–96. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 24. de Tommaso M, Delussi M, Vecchio E, *et al.*: Sleep features and central sensitization symptoms in primary headache patients. *J Headache Pain*. 2014; 15: 64. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Lipton RB, Bigal ME, Ashina S, *et al.*: Cutaneous allodynia in the migraine population. *Ann Neurol*. 2008; 63(2): 148–58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Mathew NT, Kailasam J, Seifert T: Clinical recognition of allodynia in migraine. *Neurology*. 2004; 63(5): 848–52. [PubMed Abstract](#) | [Publisher Full Text](#)
 27. **F** Lipton RB, Munjal S, Buse DC, *et al.*: Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study. *Headache*. 2016; 56(10): 1635–48. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 28. **F** Lipton RB, Munjal S, Buse DC, *et al.*: Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study. *Headache*. 2017; 57(7): 1026–40. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 29. de Tommaso M, Sciricchio V: Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives. *Curr Rheumatol Rev*. 2016; 12(2): 113–26. [PubMed Abstract](#) | [Publisher Full Text](#)
 30. Burstein R, Yarnitsky D, Goor-Aryeh I, *et al.*: An association between migraine and cutaneous allodynia. *Ann Neurol*. 2000; 47(5): 614–24. [PubMed Abstract](#) | [Publisher Full Text](#)
 31. **F** Bernstein C, Burstein R: Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. *J Clin Neurol*. 2012; 8(2): 89–99. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 32. **F** Chen N, Zhang J, Wang P, *et al.*: Functional alterations of pain processing pathway in migraine patients with cutaneous allodynia. *Pain Med*. 2015; 16(6): 1211–20. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. **F** Russo A, Esposito F, Conte F, *et al.*: Functional interictal changes of pain processing in migraine with ictal cutaneous allodynia. *Cephalalgia*. 2017; 37(4): 305–14. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 34. **F** DaSilva AF, Nascimento TD, Jassar H, *et al.*: Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. *Neurology*. 2017; 88(17): 1634–41. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 35. **F** Schwedt TJ, Zuniga L, Chong CD: Low heat pain thresholds in migraineurs between attacks. *Cephalalgia*. 2015; 35(7): 593–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 36. **F** Sand T, Zhitniy N, Nilsen KB, *et al.*: Thermal pain thresholds are decreased in the migraine preattack phase. *Eur J Neurol*. 2008; 15(11): 1199–205. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 37. Vuković V, Plavec D, Galinović I, *et al.*: Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine. *Headache*. 2007; 47(10): 1427–35. [PubMed Abstract](#) | [Publisher Full Text](#)
 38. **F** Cha YH, Lee H, Santell LS, *et al.*: Association of benign recurrent vertigo and migraine in 208 patients. *Cephalalgia*. 2009; 29(5): 550–5. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 39. Kelman L: Migraine changes with age: IMPACT on migraine classification. *Headache*. 2006; 46(7): 1161–71. [PubMed Abstract](#) | [Publisher Full Text](#)
 40. Kayan A, Hood JD: Neuro-otological manifestations of migraine. *Brain*. 1984; 107(Pt 4): 1123–42. [PubMed Abstract](#) | [Publisher Full Text](#)
 41. Lempert T, Neuhauser H: Epidemiology of vertigo, migraine and vestibular migraine. *J Neurol*. 2009; 256(3): 333–8. [PubMed Abstract](#) | [Publisher Full Text](#)
 42. Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia*. 2013; 33(9): 629–808. [PubMed Abstract](#) | [Publisher Full Text](#)
 43. Radtke A, von Brevern M, Neuhauser H, *et al.*: Vestibular migraine: long-term follow-up of clinical symptoms and vestibulo-cochlear findings. *Neurology*. 2012; 79(15): 1607–14. [PubMed Abstract](#) | [Publisher Full Text](#)
 44. Neff BA, Staab JP, Eggers SD, *et al.*: Auditory and vestibular symptoms and chronic subjective dizziness in patients with Ménière’s disease, vestibular migraine, and Ménière’s disease with concomitant vestibular migraine. *Otol Neurotol*. 2012; 33(7): 1235–44. [PubMed Abstract](#) | [Publisher Full Text](#)
 45. Neuhauser HK, Radtke A, von Brevern M, *et al.*: Migrainous vertigo: prevalence and impact on quality of life. *Neurology*. 2006; 67(6): 1028–33. [PubMed Abstract](#) | [Publisher Full Text](#)
 46. Russo A, Marcelli V, Esposito F, *et al.*: Abnormal thalamic function in patients with vestibular migraine. *Neurology*. 2014; 82(23): 2120–6. [PubMed Abstract](#) | [Publisher Full Text](#)
 47. **F** Messina R, Rocca MA, Colombo B, *et al.*: Structural brain abnormalities in patients with vestibular migraine. *J Neurol*. 2017; 264(2): 295–303. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 48. Shin JH, Kim YK, Kim HJ, *et al.*: Altered brain metabolism in vestibular migraine: comparison of interictal and ictal findings. *Cephalalgia*. 2014; 34(1): 58–67. [PubMed Abstract](#) | [Publisher Full Text](#)
 49. Bisdorff AR: Management of vestibular migraine. *Ther Adv Neurol Disord*. 2011; 4(3): 183–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Neuhauser H, Radtke A, von Brevern M, *et al.*: Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. *Neurology*. 2003; 60(5): 882–3. [PubMed Abstract](#) | [Publisher Full Text](#)
 51. **F** Lepcha A, Amalanathan S, Augustine AM, *et al.*: Flunarizine in the

- prophylaxis of migrainous vertigo: a randomized controlled trial. *Eur Arch Otorhinolaryngol.* 2014; **271**(11): 2931–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
52. von Brevern M, Neuhauser H: **Epidemiological evidence for a link between vertigo and migraine.** *J Vestib Res.* 2011; **21**(6): 299–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Uneri A: **Migraine and benign paroxysmal positional vertigo: an outcome study of 476 patients.** *Ear Nose Throat J.* 2004; **83**(12): 814–5.
[PubMed Abstract](#)
 54. Chu CH, Liu CJ, Lin LY, *et al.*: **Migraine is associated with an increased risk for benign paroxysmal positional vertigo: a nationwide population-based study.** *J Headache Pain.* 2015; **16**: 62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Jennum P, Jensen R: **Sleep and headache.** *Sleep Med Rev.* 2002; **6**(6): 471–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Kelman L: **The triggers or precipitants of the acute migraine attack.** *Cephalalgia.* 2007; **27**(5): 394–402.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Chen PK, Fuh JL, Chen SP, *et al.*: **Association between restless legs syndrome and migraine.** *J Neurol Neurosurg Psychiatry.* 2010; **81**(5): 524–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Schürks M, Winter AC, Berger K, *et al.*: **Migraine and restless legs syndrome in women.** *Cephalalgia.* 2012; **32**(5): 382–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Winter AC, Schürks M, Berger K, *et al.*: **Migraine and restless legs syndrome in men.** *Cephalalgia.* 2013; **33**(2): 130–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Dickoff DJ, Dontje SM: **Restless limbs syndrome (RLS), migraine and bruxism: A common clinical triad.** *Ann Neurol.* 2013; **74**(Suppl 17): S47.
[Reference Source](#)
 61. Karthik N, Kulkarni GB, Taly AB, *et al.*: **Sleep disturbances in 'migraine without aura'—a questionnaire based study.** *J Neurol Sci.* 2012; **321**(1–2): 73–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Seidel S, Böck A, Schlegel W, *et al.*: **Increased RLS prevalence in children and adolescents with migraine: a case-control study.** *Cephalalgia.* 2012; **32**(9): 693–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 63. Lucchesi C, Bonanni E, Maestri M, *et al.*: **Evidence of increased restless legs syndrome occurrence in chronic and highly disabling migraine.** *Funct Neurol.* 2012; **27**(2): 91–4.
[PubMed Abstract](#) | [Free Full Text](#)
 64. Rhode AM, Hösing VG, Happe S, *et al.*: **Comorbidity of migraine and restless legs syndrome—a case-control study.** *Cephalalgia.* 2007; **27**(11): 1255–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. D'Andrea G, Leon A: **Pathogenesis of migraine: from neurotransmitters to neuromodulators and beyond.** *Neurol Sci.* 2010; **31**(Suppl 1): S1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Salas RE, Gamaldo CE, Allen RP: **Update in restless legs syndrome.** *Curr Opin Neurol.* 2010; **23**(4): 401–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Sakai Y, Dobson C, Diksic M, *et al.*: **Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis.** *Neurology.* 2008; **70**(6): 431–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Chen PK, Fuh JL, Wang SJ: **Bidirectional triggering association between migraine and restless legs syndrome: A diary study.** *Cephalalgia.* 2016; **36**(5): 431–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. **F** Valente M, Janes F, Russo V, *et al.*: **Prevalence of Restless Legs Syndrome in Migraine Patients: A Case-Control Study. Analysis of Risk Factors for Restless Legs Syndrome in Migraine Patients.** *Headache.* 2017; **57**(7): 1088–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 70. Fuh JL, Chung MY, Yao SC, *et al.*: **Susceptible genes of restless legs syndrome in migraine.** *Cephalalgia.* 2016; **36**(11): 1028–37.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Bigal ME, Lipton RB: **The epidemiology, burden, and comorbidities of migraine.** *Neurol Clin.* 2009; **27**(2): 321–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Whiteford HA, Degenhardt L, Rehm J, *et al.*: **Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.** *Lancet.* 2013; **382**(9904): 1575–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Breslau N, Davis GC: **Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults.** *J Psychiatr Res.* 1993; **27**(2): 211–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Breslau N, Lipton RB, Stewart WF, *et al.*: **Comorbidity of migraine and depression: investigating potential etiology and prognosis.** *Neurology.* 2003; **60**(8): 1308–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Antonaci F, Nappi G, Galli F, *et al.*: **Migraine and psychiatric comorbidity: a review of clinical findings.** *J Headache Pain.* 2011; **12**(2): 115–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Peterlin BL, Katsnelson MJ, Calhoun AH: **The associations between migraine, unipolar psychiatric comorbidities, and stress-related disorders and the role of estrogen.** *Curr Pain Headache Rep.* 2009; **13**(5): 404–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Oedegaard KJ, Neckelmann D, Mykletun A, *et al.*: **Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study.** *Cephalalgia.* 2006; **26**(1): 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Tietjen GE, Brandes JL, Digre KB, *et al.*: **High prevalence of somatic symptoms and depression in women with disabling chronic headache.** *Neurology.* 2007; **68**(2): 134–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Buse DC, Silberstein SD, Manack AN, *et al.*: **Psychiatric comorbidities of episodic and chronic migraine.** *J Neurol.* 2013; **260**(8): 1960–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Baskin SM, Smitherman TA: **Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications.** *Neurol Sci.* 2009; **30**(Suppl 1): S61–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Lirng JF, Chen HC, Fuh JL, *et al.*: **Increased myo-inositol level in dorsolateral prefrontal cortex in migraine patients with major depression.** *Cephalalgia.* 2015; **35**(8): 702–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Merikangas KR, Merikangas JR, Angst J: **Headache syndromes and psychiatric disorders: association and familial transmission.** *J Psychiatr Res.* 1993; **27**(2): 197–210.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Breslau N, Davis GC, Andreski P: **Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults.** *Psychiatry Res.* 1991; **37**(1): 11–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Low NC, Du Fort GG, Cervantes P: **Prevalence, clinical correlates, and treatment of migraine in bipolar disorder.** *Headache.* 2003; **43**(9): 940–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 85. Ortiz A, Cervantes P, Zlotnik G, *et al.*: **Cross-prevalence of migraine and bipolar disorder.** *Bipolar Disord.* 2010; **12**(4): 397–403.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Chen YC, Tang CH, Ng K, *et al.*: **Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan.** *J Headache Pain.* 2012; **13**(4): 311–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 87. **F** Gordon-Smith K, Forty L, Chan C, *et al.*: **Rapid cycling as a feature of bipolar disorder and comorbid migraine.** *J Affect Disord.* 2015; **175**: 320–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 88. **F** Gigante AD, Barenboim IY, Dias Rda S, *et al.*: **Rapid cycling bipolar disorder is associated with a higher lifetime prevalence of migraine.** *Acta Psychiatr Scand.* 2015; **132**(4): 308–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 89. Breslau N: **Psychiatric comorbidity in migraine.** *Cephalalgia.* 1998; **18**(Suppl 22): 56–8; discussion 58–61.
[PubMed Abstract](#)
 90. Baskin SM, Lipchik GL, Smitherman TA: **Mood and anxiety disorders in chronic headache.** *Headache.* 2006; **46**(Suppl 3): S76–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
 91. Goulart AC, Santos IS, Brunoni AR, *et al.*: **Migraine headaches and mood/anxiety disorders in the ELSA Brazil.** *Headache.* 2014; **54**(8): 1310–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Smitherman TA, Kolivas ED, Bailey JR: **Panic disorder and migraine: comorbidity, mechanisms, and clinical implications.** *Headache.* 2013; **53**(1): 23–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. **F** Rocha-Filho PA, Marques KS, Torres RC, *et al.*: **Migraine, Osmophobia, and Anxiety.** *Pain Med.* 2016; **17**(4): 776–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Andrew Charles

Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA

Competing Interests: No competing interests were disclosed.

2. Charly Gaul

Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research